WithdrawnNCT05401019
Efficacy of Treatment With Pramipexole or Risperidone in Patients With Refractory OCD (OCD)
Researchers are comparing Pramipexole and Risperidone to find out how the approaches affect obsessive thoughts and compulsive behaviours in people with OCD.
Medication studyAges 18–64
Understand this study
What is this study about?
Researchers are comparing Pramipexole and Risperidone to find out how the approaches affect obsessive thoughts and compulsive behaviours in people with OCD.
Who could participate?
This study is for people with OCD. Listed age limits: 18 years to 64 years. Other eligibility criteria apply.
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateEstimated: June 2022
- Recruitment status
- Withdrawn
- Enrollment listed in the registry
- 0
- Sponsor
- Clinical Academic Center (2CA-Braga)
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Not clearly listed
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT05401019
- Official title
Show the full official title
Efficacy of Treatment With Pramipexole or Risperidone in Patients With Refractory Obsessive-compulsive Disorder (OCD): Randomized Controlled Trial
Recruitment & locations
WithdrawnLocations not listed
Questions about this study
What is this study about?
Researchers are comparing Pramipexole and Risperidone to find out how the approaches affect obsessive thoughts and compulsive behaviours in people with OCD.
Who is behind this study?
The study sponsor is Clinical Academic Center (2CA-Braga).
Does this study involve medication?
Yes. The study involves medication, including Pramipexole and Risperidone.
Who can participate?
This study is for people with OCD. Listed age limits: 18 years to 64 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as withdrawn.
